Immunoscript Life Science has secured $8.9 million from CEPI to advance clinical testing of a new RNA vaccine platform that can be stored at regular refrigeration temperatures, addressing the cold chain challenge in vaccine distribution. This breakthrough is crucial for improving global access to vaccines, especially in remote and low-resource areas, enhancing preparedness against future pandemics and emerging diseases.
Read the full article at Digital Journal
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.



